HC Wainwright Reaffirms Buy Rating for Aligos Therapeutics (NASDAQ:ALGS)

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $75.00 price objective on the stock.

Aligos Therapeutics Stock Up 25.2 %

Shares of NASDAQ ALGS opened at $9.03 on Wednesday. The company has a market cap of $705.33 million, a price-to-earnings ratio of -7.05 and a beta of 2.16. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $30.00. The firm’s 50-day simple moving average is $10.69 and its 200 day simple moving average is $13.65.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The business had revenue of $1.06 million for the quarter. During the same period last year, the company earned ($10.75) earnings per share. On average, equities analysts expect that Aligos Therapeutics will post -8.2 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its stake in shares of Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after purchasing an additional 171,490 shares during the last quarter. Opaleye Management Inc. lifted its holdings in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after buying an additional 333,000 shares during the period. Finally, Armistice Capital LLC lifted its holdings in Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares during the period. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).